Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children

Archives of Disease in Childhood: Education and Practice Edition

Volumn 89, Issue 2, 2004, Pages

  Turner, Sean ^a   Ford, Violet ^a  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; ETORICOXIB; IBUPROFEN; LODINE SR; LUMIRACOXIB; MELOXICAM; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PARECOXIB; ROFECOXIB; VALDECOXIB;

ADOLESCENT; ALLERGIC VASCULITIS; ASEPTIC MENINGITIS; BARTTER SYNDROME; BLEEDING; DRUG HALF LIFE; DRUG TOLERABILITY; DYSMENORRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MENTAL DISEASE; OSTEOARTHRITIS; POSTOPERATIVE NAUSEA AND VOMITING; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SCHOOL CHILD; SOLID TUMOR; TOXIC EPIDERMAL NECROLYSIS; VISUAL IMPAIRMENT;

EID: 4944247252     PISSN: 17430585     EISSN: None     Source Type: Journal    
DOI: 10.1136/adc.2004.055186     Document Type: Review

References (33)

1. National Prescribing Centre. COX-II selective inhibitors. MeReC Briefing, 2002;Issue 20, 5-8.
2. National Institute for Clinical Excellence. Guidance on the use of cyclooxyenase (COX) II inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisal Guidance No. 27, July, 2001.
3. Joint Formulary Committee. British National Formulary, 47th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2004, http://bnf.org/bnf/bnf/current/doc/5183.htm.
4. Stempak D, Gammon J, Klein J, et al. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 2002;72:490-7.
5. St Rose E, Ferrandiz M, Kiss M, et al. Steady-state plasma concentrations of rofecoxib in children (ages 2-5 years) with juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44:S291.
6. Edwards DJ, Prescella RP, Fratorelli DA, et al. Pharmacokinetics of rofecoxib in children [abstract]. Clin Pharmacol Ther 2004;75:73.
7. Boni JP, Korth-Bradley JM, Martin P, et al. Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis. Clin Ther 1999;21:1715-24.
8. Lie HKH, Turner SC. Early experience with the use of celecoxib in a child and adolescent population. Journal of Pharmacy Practice and Research 2002;32:27-31.
9. Møiniche S, Rømsing J, Dahl JB, et al. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth Anal 2003;96:68-77.
10. Pickering AE, Bridge HS, Nolan J, et al. Double-blind, placebo controlled analgesic study of ibuprofen or rofecoxib in combination with paracetamol for tonsillectomy in children. Br J Anaesth 2002;88:72-7.
11. Joshi W, Connelly NR, Reuben SS, et al. An evaluation of the safety and efficacy of administering rofecoxib for post operative pain management. Anesth Analg 2003;97:35-8.
12. Vallee E, Lafrenaye S, Dorion D. Rofecoxib in pain control after tansillectomy in children [abstract]. Pain 2004;5:S84.
13. Munro JE, Murray KJ. Advances in paediatric rheumatology: Beyond NSAIDs and joint replacement. J Paediatr Child Health 2004;40:161-9.
14. Fahey SM, Silver RM. Use of NSAIDs and COX-2 inhibitors in children with musculoskeletal disorders. J Pediatr Orthop 2003;23:794-9.
15. Kiss MH, Reiff AA, Reicin AS, et al. Rofecoxib demonstrates efficacy and tolerability in children and adolescents (ages 2-17 years) with juvenile rheumatoid arthritis (JRA) in a 23-week randomized study. 67 Annual Scientific Meeting of the American College of Rheumatology [abstract].
16. Foeldvari I, Burgos-Vargas R, Thon A, et al. High response rate in the phase 1/11 study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1079-83.
17. Foeldvari I. A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen. Clin Exp Rheumatol 2002;20:87A.
18. Dickens DS, Kozielski R, Khan J, et al. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 2002;5:356-64.
19. National Institute of Health. Vinblastine, celecoxib, and combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma family of tumours. Children's Oncology Group. http://clinicaltrials.gov/ ct/show/NCT000618937order=42 (Accessed July 2004).
20. Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhoea J Pediatr Adolesc Gynecol 2004;17:75-9.
21. Kleta R, Basoglu C, Kuwertz-Broking E. New treatment options for Bartter's Syndrome [letter]. N Engl J Med 2000;343:661-2.
22. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002;87:462-7.
23. Keenan GF, Giannini EH, Atherya. Clinically significant gastropathy associated with non steroidal anti inflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 1995;22:1149-51.
24. Adverse Drug Reaction Advisory Committee (ADRAC). Serious gastrointestinal effects with celecoxib and rofecoxib. Australian Adverse Drug Reactions Bulletin 2003;22:15.
25. Adverse Drug Reaction Advisory Committee (ADRAC). Acute neuropsychiatric events with celecoxib and rofecoxib. Australian Adverse Drug Reactions Bulletin 2003;22:3.
26. Schneider F, Meziani F, Chartier C, et al. Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852-3.
27. Ashwath ML, Katner HP. Recurrent aseptic meningitis due to different nonsteroidal anti-inflammatory drugs including rofecoxib. Postgrad Med J 2003;79:295-6.
28. Coulter DM, Clark DWJ, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 2003;327:1214-5.
29. Glasser DL, Burroughs SH. Valdecoxib induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003;23:551-3.
30. Berger P, Dwyer D, Corallo CE. Toxic epidermal necrolysis after celecoxib Therapy. Pharmacotherapy 2002;22:1193-5.
31. Adverse Drug Reaction Advisory Committe (ADRAC). Parecoxib-one shot only. Australian Adverse Drug Reactions Bulletin 2004;23:10-11.
32. Mukherjee D, Nissen SE, Topal EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
33. Lipsky PE, Brooks P, Crofford U. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000;160:913-20.